KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Asset Writedowns and Impairment (2017 - 2020)

Historic Asset Writedowns and Impairment for Resmed (RMD) over the last 9 years, with Q1 2020 value amounting to $9.1 million.

  • Resmed's Asset Writedowns and Impairment rose 5576.86% to $9.1 million in Q1 2020 from the same period last year, while for Mar 2020 it was $20.7 million, marking a year-over-year increase of 2355.43%. This contributed to the annual value of $15.0 million for FY2019, which is 2944.88% up from last year.
  • Resmed's Asset Writedowns and Impairment amounted to $9.1 million in Q1 2020, which was up 5576.86% from $2.8 million recorded in Q4 2019.
  • Over the past 5 years, Resmed's Asset Writedowns and Impairment peaked at $9.1 million during Q1 2020, and registered a low of $382000.0 during Q1 2017.
  • Over the past 4 years, Resmed's median Asset Writedowns and Impairment value was $1.7 million (recorded in 2018), while the average stood at $3.3 million.
  • In the last 5 years, Resmed's Asset Writedowns and Impairment skyrocketed by 48324.8% in 2018 and then crashed by 2216.23% in 2019.
  • Over the past 4 years, Resmed's Asset Writedowns and Impairment (Quarter) stood at $1.3 million in 2017, then fell by 3.41% to $1.2 million in 2018, then surged by 126.68% to $2.8 million in 2019, then soared by 221.67% to $9.1 million in 2020.
  • Its Asset Writedowns and Impairment stands at $9.1 million for Q1 2020, versus $2.8 million for Q4 2019 and $2.6 million for Q3 2019.